Health Care

BL1107 phase‑2 failure forces Bausch + Lomb to pivot away from glaucoma, refocusing on proven eye‑care products and new R&D prospects.

Nurix Therapeutics reports Q2 2026 earnings miss, but highlights Roche partnership and protein‑level modulation pipeline, signaling continued focus on innovative treatments.

ATAI Life Sciences NV’s AtaiBeckley Inc. plans a $5.17‑share sale of 100,000 shares by a director, revealing key financial strategy and compliance for investors.

Amgen shares slip 2% on July 9, 2026 while Nasdaq climbs, amid FDA approval of a new oncology biosimilar that could reshape the biotech race.

Satellos Bioscience’s interim TRAILHEAD data show significant fat‑fraction reduction, improved endurance, and low CK levels—hinting at a breakthrough DMD therapy that’s boosting analyst optimism and stock upside.

Recursion Pharmaceuticals sells 200k shares as insider Gibson divests amid a $3.72 stock price and negative P/E, highlighting investor uncertainty and a tech‑driven biotech pivot.

Vertex’s $10 B takeover of Crinetics expands its portfolio into endocrinology, adding Phase III assets and boosting revenue potential.

QTREX Quantum Ltd. amends its F‑1, expanding to 1.8 M shares and redirecting proceeds to R&D of respiratory‑support tech, positioning itself as a non‑invasive ventilation alternative.

VeraDermics: A $5.1B biopharma eyeing dermatology breakthroughs amid sharp stock swings, a negative P/E, and fierce competition.

VSee Health’s new convertible notes boost liquidity and growth, showing how the digital‑health firm secures capital while protecting shareholders.